|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
We hypothesized that GIP is anabolic in human subcutaneous adipose tissue (SAT) promoting triacylglycerol (TAG) deposition through reesterification of nonesterified fatty acids (NEFA), and this effect may differ according to obesity status or glucose tolerance.
|
28073779 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 and GIP combination is suggested as a promising therapeutic strategy for treatment of obesity and diabetes.
|
28610922 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the role of GIP in hyperphagia induced obesity and metabolic abnormalities in leptin deficient (Lep<sup>ob/ob</sup>) mice.
|
28271035 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The effect of GIP on obesity measures was substantially different between men and women.
|
26505824 |
2016 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In humans, genomewide association studies have identified single nucleotide polymorphisms (SNPs) in the GIPR gene that are strongly associated with body mass index (BMI); however, it is not clear whether genetic variations in the GIP gene are involved in the development of obesity.
|
25324507 |
2014 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Since glucose-dependent insulinotropic polypeptide (GIP) is a strong stimulator of adipogenesis and may play a role in the development of obesity, we explored whether GIP directly would stimulate OPN expression in adipose tissue and thereby induce insulin resistance.
|
23349498 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide [also known as gastric inhibitory polypeptide (GIP)] and its receptor (GIPR) may link overnutrition to obesity, insulin resistance, and type 2 diabetes.
|
22237064 |
2012 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide is secreted after food consumption and gipr knockout mice fed a high-fat diet are protected against obesity and disturbances in glucose homeostasis.
|
22399504 |
2012 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Therefore, elevated Pro-CT and CGRP-I levels in obesity might result from GIP-induced Pro-CT and CGRP-I release in AT and might be triggered by a high-fat diet.
|
21106708 |
2011 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of GIP, which occurs in obesity, might thereby be contributing to the enhanced rate of carcinogenesis observed in obesity.
|
20433877 |
2010 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) was recently linked to adipocyte metabolism and obesity-related metabolic disorders, including NAFLD, induced by an excess of saturated fatty acids (SFAs), but its role in vivo, as well as underlying mechanisms, is unknown.
|
19141695 |
2009 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Gastric inhibitory polypeptide (GIP) is postulated to be involved in type 2 diabetes mellitus and obesity.
|
19254363 |
2009 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent studies in rodents suggested that GIP directly links overnutrition to obesity.
|
17395281 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
RGD |
In conclusion, both obese and diabetic rats had an impaired early-phase insulinotropic effect of GIP due to impaired gene expression of GIP-Rs which could be a potential target to prevent transition of obesity to diabetes and to improve insulin secretion in the latter.
|
18063845 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, observations in transgenic GIP receptor deficient mice indicate that GIP directly links overnutrition to obesity, therein playing a crucial role in the development of obesity and related metabolic disorders.
|
14607102 |
2003 |